# Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

> **NCT00099619** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 138 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide/insulin glargine
- **DRUG:** insulin glargine/exenatide

## Key facts

- **NCT ID:** NCT00099619
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099619, "Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00099619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*